Abstract
Summary
KEY FINDINGS
The global veterinary vaccines market growth is estimated to progress at a CAGR of 7.37% during the forecast period, 2022-2030. The key market growth factors include the increasing vaccination drives by government agencies, the rising demand for vaccines due to the growing animal population and diseases, and advanced vaccines R&D.
MARKET INSIGHTS
The veterinary vaccines market is a key segment of the veterinary pharmaceuticals market and thereby entails product offerings like animal pharmaceuticals, parasiticides, antimicrobials, and antimicrobials.
Further, governments worldwide are running nationwide programs, campaigns, and initiatives to address the problem and tackle the disease's effects on animal health. These act as growth drivers for the veterinary industry. In addition, the governments collaborate with market players to exchange skills, knowledge, and technology that enhance the impact of the vaccination drives. For instance, the Foot and Mouth Disease (FMD) is part of India's National Animal Disease Control Programme, undertaken for protection against FMD in cattle. For this, the Indian government has earmarked over Rs.13000 crores with the aim of containing the disease by 2025. Such aspects drive the global veterinary vaccines market growth. However, the market growth is restricted by the lack of skilled professionals and awareness among farmers.
REGIONAL INSIGHTS
The global veterinary vaccines market growth analysis includes the geographical assessment of North America, Europe, Asia-Pacific, and Rest of World. North America is the largest revenue-generating region in the global market. This is accredited to the growing awareness among vaccines and acceptance of vaccines use to improve health.
COMPETITIVE INSIGHTS
The market competition is high, with several active players engaged in selling and manufacturing vaccines. Some of the eminent firms in the market are Elanco Animal Health, Zoetis Inc, Boehringer Ingelheim Animal Health, Merck Animal Health, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
1 RESEARCH SCOPE & METHODOLOGY
1.1 STUDY OBJECTIVES
1.2 SCOPE OF STUDY
1.3 METHODOLOGY
1.4 ASSUMPTIONS & LIMITATIONS
2 EXECUTIVE SUMMARY
2.1 MARKET SIZE & ESTIMATES
2.2 MARKET OVERVIEW
3 MARKET DYNAMICS
3.1 KEY DRIVERS
3.1.1 RESEARCH & DEVELOPMENT OF ADVANCED VACCINES
3.1.2 NEED OF VACCINE DUE TO RISING ANIMAL POPULATION AND DISEASES
3.1.3 VACCINATION DRIVES BY GOVERNMENT AGENCIES
3.2 KEY RESTRAINTS
3.2.1 RULES & REGULATIONS FOR THE USE OF VACCINE
3.2.2 LACK OF AWARENESS AMONG FARMERS AND REQUIREMENT OF SKILLED VETERINARIANS
4 KEY ANALYTICS
4.1 IMPACT OF COVID-19 ON VETERINARY VACCINES MARKET
4.2 KEY MARKET TRENDS
4.3 PORTER’S FIVE FORCES ANALYSIS
4.3.1 BUYERS POWER
4.3.2 SUPPLIERS POWER
4.3.3 SUBSTITUTION
4.3.4 NEW ENTRANTS
4.3.5 INDUSTRY RIVALRY
4.4 VALUE CHAIN ANALYSIS
4.5 KEY BUYING CRITERIA
4.6 REGULATORY FRAMEWORK
5 MARKET BY ANIMAL TYPE
5.1 LIVESTOCK ANIMAL
5.1.1 CATTLE
5.1.2 PIGS
5.1.3 POULTRY
5.1.4 SHEEP
5.1.5 OTHER LIVESTOCK ANIMALS
5.2 COMPANION ANIMAL
5.2.1 CANINE
5.2.2 FELINE
5.2.3 EQUINE
5.3 AQUACULTURE
6 MARKET BY PRODUCT TYPE
6.1 ATTENUATED VACCINES
6.2 INACTIVATED VACCINES
6.3 TOXOID VACCINES
6.4 CONJUGATE VACCINES
6.5 DNA VACCINES
6.6 RECOMBINANT VACCINES
6.7 SUBUNIT VACCINES
7 MARKET BY DISEASE TYPE
7.1 CANINE DISEASE
7.2 PORCINE DISEASE
7.3 BOVINE DISEASE
7.4 POULTRY DISEASE
7.5 AQUACULTURE DISEASE
7.6 OTHER DISEASES
8 GEOGRAPHICAL ANALYSIS
8.1 NORTH AMERICA
8.1.1 MARKET SIZE & ESTIMATES
8.1.2 KEY GROWTH ENABLERS
8.1.3 KEY CHALLENGES
8.1.4 KEY PLAYERS
8.1.5 COUNTRY ANALYSIS
- 8.1.5.1 UNITED STATES
- 8.1.5.2 CANADA
8.2 EUROPE
8.2.1 MARKET SIZE & ESTIMATES
8.2.2 KEY GROWTH ENABLERS
8.2.3 KEY CHALLENGES
8.2.4 KEY PLAYERS
8.2.5 COUNTRY ANALYSIS
- 8.2.5.1 UNITED KINGDOM
- 8.2.5.2 GERMANY
- 8.2.5.3 FRANCE
- 8.2.5.4 ITALY
- 8.2.5.5 RUSSIA
- 8.2.5.6 BELGIUM
- 8.2.5.7 POLAND
- 8.2.5.8 REST OF EUROPE
8.3 ASIA-PACIFIC
8.3.1 MARKET SIZE & ESTIMATES
8.3.2 KEY GROWTH ENABLERS
8.3.3 KEY CHALLENGES
8.3.4 KEY PLAYERS
8.3.5 COUNTRY ANALYSIS
- 8.3.5.1 CHINA
- 8.3.5.2 JAPAN
- 8.3.5.3 INDIA
- 8.3.5.4 SOUTH KOREA
- 8.3.5.5 INDONESIA
- 8.3.5.6 THAILAND
- 8.3.5.7 VIETNAM
- 8.3.5.8 AUSTRALIA & NEW ZEALAND
- 8.3.5.9 REST OF ASIA-PACIFIC
8.4 REST OF WORLD
8.4.1 MARKET SIZE & ESTIMATES
8.4.2 KEY GROWTH ENABLERS
8.4.3 KEY CHALLENGES
8.4.4 KEY PLAYERS
8.4.5 REGIONAL ANALYSIS
- 8.4.5.1 LATIN AMERICA
- 8.4.5.2 MIDDLE EAST & AFRICA
9 COMPETITIVE LANDSCAPE
9.1 KEY STRATEGIC DEVELOPMENTS
9.1.1 MERGERS & ACQUISITIONS
9.1.2 PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3 PARTNERSHIPS & AGREEMENTS
9.1.4 BUSINESS EXPANSIONS & DIVESTITURES
9.2 COMPANY PROFILES
9.2.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
9.2.2 BRILLIANT BIO PHARMA
9.2.3 CEVA SANTE ANIMALE
9.2.4 ELANCO ANIMAL HEALTH
9.2.5 HESTER BIOSCIENCES LTD
9.2.6 HIPRA
9.2.7 INDIAN IMMUNOLOGICALS LIMITED
9.2.8 MERCK ANIMAL HEALTH
9.2.9 PHIBRO ANIMAL HEALTH
9.2.10 VAXXINOVA GMBH
9.2.11 VIRBAC SA
9.2.12 ZOETIS